Modifications of α2-Plasmin Inhibitor During Treatments by a Defibrinating Agent

1979 ◽  
Author(s):  
M. Samama ◽  
J. Conard ◽  
B. Cazenave ◽  
A. Derlon ◽  
A. Gaudric ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Antithrombin Iii ◽  
Fibrinogen Level ◽  
Plasma Viscosity ◽  
Inhibitor Complex ◽  
Vein Occlusion ◽  
Crossed Immunoelectrophoresis ◽  
Α2 Macroglobulin ◽  
Plasmin Inhibitor ◽  
Soluble Complexes

A defibrination agent (Defibrase®) has been administered to 8 patients with retinal vein occlusion. Defibrase has been infused sub-cutaneously at a dose of 0.5 B. U./kg/day for 5 days followed by 1 to 2 B.U./kg twice a week, for 2 other weeks, so that fibrinogen level was maintained below 100 mg/100 ml. The tests performed were the following : fibrinogen, FDP, soluble complexes, plasminogen, α2 macroglobulin, antithrombin III, α2-plasmin inhibitor (amidolytic and Laurell methods), blood and plasma viscosity. They have been done before treatment and repeated daily for 5 days and then on the 8th, 11th, 14th and 21st day.A decrease in fibrinogen, viscosity, plasminogen and an increase in FDP and soluble complexes have been observed, as already described. The results of the α2- plasmin inhibitor shows a decrease of about 50 % that is slightly more pronounced by the Laurell method than the amidolytic method. The plasmin-α2 plasmin inhibitor complex detected by crossed immunoelectrophoresis is present in various amounts.

Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors

2009 ◽  
Vol 101 (05) ◽  
pp. 818-826 ◽  
Author(s):  
Torben Elm ◽  
Mirella Ezban ◽  
Thomas Krogh ◽  
Ditte Karpf ◽  
Anne Steinø ◽  
...  
Keyword(s):  
Complex Formation ◽  
Antithrombin Iii ◽  
Factor Viia ◽  
Factor Vii ◽  
Elimination Kinetics ◽  
Inhibitor Complex ◽  
Α2 Macroglobulin ◽  
Clearance Mechanism ◽  
Deficient Mice

SummaryThe mechanism for the elimination of factor VII (FVII) from the circulation is unknown, just as it is unclear how activation of FVII to FVIIa and subsequent complex formation with antithrombin III (AT) or α2-macroglobulin (α2M) affects clearance. The possibility that the clearance mechanism involves activation and inhibitor complex formation as obligatory intermediate reactions is examined in this study. Human and murine sera were spiked with human FVIIa in the absence and presence of heparin and analysed for complex formation. Complex formation in vivo was studied after intravenous injection of 125I-VIIa in mice; and the pharmacokinetics (PK) of human and murine FVIIa was studied in normal mice. Furthermore, comparative PK studies were performed with FVII, FVIIa, active site blocked FVIIa and a preformed FVIIa-AT complex in normal and α2M-deficient mice. The data demonstrated that FVIIa-AT complexes and to a much lesser extent FVIIa-α2M-complexes accumulated in vivo after FVIIa administration. FVIIa-AT accounted for about 50% of total FVIIa antigen left in the circulation after 3 hours. All FVII derivatives studied including FVII, FVIIa and FVIIa-AT were cleared with similar rates suggesting an elimination kinetics which is unaffected by FVII activation and subsequent inactivation by plasma inhibitors.

Application of Crossed Radio Immunoelectrophoresis for the Demonstration of Thrombin Binding Proteins in Human Plasma

1979 ◽  
Author(s):  
L. Grimmer ◽  
L. Aukrust ◽  
P. Andersen
Keyword(s):  
Human Serum ◽  
Human Plasma ◽  
Binding Proteins ◽  
Antithrombin Iii ◽  
Crossed Immunoelectrophoresis ◽  
Α2 Macroglobulin

In order to demonstrate thrombin binding proteins in human plasma in a direct way, crossed Immunoelectrophoresis (CIE) presipitates were prepared by using human plasma and anti human serum. These presipitates were incubated with 125 I-thrombin and subsequently subjected to autoradiography. Binding of thrombin was demonstrated to α2-macroglobulin only By preiricubating heat defibrinated plasma with 125I-thrombin prior to CIE and performing autoradiography without further incubation with 125I-thrombin, binding to antithrombin III was demonstrated as well. No binding of thrombin to α1-antitrypsin was observed in any of the experiments.

Role of haemorheological factors in patients with retinal vein occlusion

2007 ◽  
Vol 98 (12) ◽  
pp. 1215-1219 ◽  
Author(s):  
Lucia Mannini ◽  
Rossella Marcucci ◽  
Paola Bolli ◽  
Andrea Sodi ◽  
Barbara Giambene ◽  
...  
Keyword(s):  
Shear Rate ◽  
Retinal Vein Occlusion ◽  
Healthy Subjects ◽  
Univariate Analysis ◽  
Plasma Viscosity ◽  
Shear Rates ◽  
Vein Occlusion ◽  
Rotational Viscosimeter ◽  
And Gender

SummaryRetinal vein occlusion (RVO) is an important cause of permanent visual loss. Hyperviscosity, due to alterations of blood cells and plasma components, may play a role in the pathogenesis of RVO. Aim of this case-control study was to evaluate the possible association between haemorheology and RVO. In 180 RVO patients and in 180 healthy subjects comparable for age and gender we analysed the whole haemorheological profile: [whole blood viscosity (WBV), erythrocyte deformability index (DI), plasma viscosity (PLV), and fibrinogen]. WBV and PLV were measured using a rotational viscosimeter, whereas DI was measured by a microcomputer-assisted filtrometer. WBV at 0.512 sec-1 and 94.5 sec-1 shear rates as well as DI, but not PLV, were found to be significantly different in patients as compared to healthy subjects. At the logistic univariate analysis,a significant association between the highest tertiles of WBV at 94.5 sec-1 shear rate (OR:4.91,95%CI 2.95–8.17;p<0.0001),WBV at 0.512 sec-1 shear rate (OR: 2.31, 95%CI 1.42–3.77; p<0.0001), and the lowest tertile of DI (OR: 0.18, 95%CI 0.10–0.32; p<0.0001) and RVO was found. After adjustment for potential confounders,the highest tertiles of WBV at 0.512 sec-1 shear rate (OR: 3.23, 95%CI 1.39–7.48; p=0.006),WBV at 94.5 sec-1 shear rate (OR: 6.74, 95%CI 3.06–14.86; p<0.0001) and the lowest tertile of DI (OR:0.20,95%CI 0.09–0.44,p<0.0001) remained significantly associated with the disease. In conclusion,our data indicate that an alteration of haemorheological parameters may modulate the susceptibility to the RVO, by possibly helping to identify patients who may benefit from haemodilution.

scholarly journals Thrombin-antithrombin III Complex and Plasmin-α2 plasmin inhibitor Complex during Pregnancy

1993 ◽  
Vol 4 (2) ◽  
pp. 116-120
Author(s):  
Hiroo ONDA ◽  
Akiteru TOKUNAGA ◽  
Hiroshi TOMA ◽  
Masayoshi SANADA ◽  
Kazue TAKAI
Keyword(s):  
Antithrombin Iii ◽  
Inhibitor Complex ◽  
Thrombin Antithrombin Iii Complex ◽  
Plasmin Inhibitor
Sign in / Sign up

Export Citation Format

Share Document